Work

Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial

Year: 2020

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(20)30609-7

Authors: David Rosmarin, Amit G Pandya, Mark Lebwohl, Pearl Grimes, Iltefat Hamzavi, Alice B Gottlieb, Kathleen Butler, Fiona Kuo, Kang Sun, Tao Ji, Michael D Howell, John E Harris

Institutions: Tufts Medical Center, Palo Alto Medical Foundation, The University of Texas Southwestern Medical Center, Icahn School of Medicine at Mount Sinai, Vitiligo and Pigmentation Institute of Southern California, Henry Ford Health, Henry Ford Hospital, Incyte (United States), University of Massachusetts Chan Medical School

Language: English

Topic: melanin and skin pigmentation

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3041952258

FWCI: 12.74

Cites: 31

Cited by: 284

Related to: 10